<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02498860</url>
  </required_header>
  <id_info>
    <org_study_id>CNUHH-2015-7</org_study_id>
    <nct_id>NCT02498860</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of Lung</brief_title>
  <acronym>APICAL</acronym>
  <official_title>Efficacy and Safety of Pemetrexed Plus Cisplatin as Combination Chemotherapy for Post-operative Adenocarcinoma : Multi-center, Single Arm, Open-label, Phase â…¡ Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kosin University Gospel Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chungnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyungpook National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pusan National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chonnam National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Two-Year Disease Free Survival Rate of Stage IB~IIIA adenocarcinoma after Adjuvant&#xD;
      Chemotherapy with Pemetrexed and Cisplatin will be assessed. A total of 106 patients will be&#xD;
      recruited for 12 months, and followed for two years, thus the duration of study will be 36&#xD;
      months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary endpoint : 2 year disease free survival&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
      Overall survival, Frequency and severity of adverse events&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2015</start_date>
  <completion_date type="Actual">July 31, 2021</completion_date>
  <primary_completion_date type="Actual">February 6, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival rate</measure>
    <time_frame>2 year</time_frame>
    <description>Disease free survival time is measured from the date of enrollment to date of tumor recurrence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>4 year</time_frame>
    <description>Overall survival time is measured from the date of enrollment to date of death from any cause. Participants who are alive when the data lock or is lost to follow-up will have their overall survival time censored on the last date the participant is known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>4 months</time_frame>
    <description>adverse events using common terminology criteria for adverse events 4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Adenocarcinoma</condition>
  <condition>Lung Neoplasm</condition>
  <arm_group>
    <arm_group_label>Pemebit plus Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pemetrexed (Pemebit 500 mg/m2) plus cisplatin (75 mg/m2) every 3 weeks up to 4 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemebit</intervention_name>
    <description>500mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles</description>
    <arm_group_label>Pemebit plus Cisplatin</arm_group_label>
    <other_name>Pemetrexed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>75mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles</description>
    <arm_group_label>Pemebit plus Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adenocarcinoma of Lung&#xD;
&#xD;
          -  Postoperative pathologic stage IB~IIIA&#xD;
&#xD;
          -  Complete surgical resection (R0 resection) N1-2: R0 resection with lobectomy and&#xD;
             mediastinal lymph nodes dissection (MLND) N0: R0 resection with lobectomy with or&#xD;
             without MLND&#xD;
&#xD;
          -  Adjuvant treatment should start between 4 to 6 weeks after surgery&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Weight loss during last 3 months should be less than 10%.&#xD;
&#xD;
          -  Normal hematologic, hepatic and renal function Neutrophil count &gt; 1500 /microliter,&#xD;
             Platelet &gt; 100,000/microliter, Hemoglobin &gt; 9 g/dL Bilirubin &lt;=1.5 x upper limit&#xD;
             normal, transaminase &lt; 2.5 x upper limit normal Serum Creatinine &lt;=1.5 mg/dL&#xD;
&#xD;
          -  Women in child bearing age should consent using contraceptive measures, and must have&#xD;
             negative pregnancy test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other malignant neoplastic disease within 5 years.&#xD;
&#xD;
          -  Neoadjuvant chemotherapy before surgery of lung cancer&#xD;
&#xD;
          -  Patients who will be treated with postoperative radiation.&#xD;
&#xD;
          -  Stage IIIB or IV lung cancer&#xD;
&#xD;
          -  Severe infection, or cardiorespiratory, hematologic illness&#xD;
&#xD;
          -  HIV positive cases&#xD;
&#xD;
          -  Pregnancy or lactating women&#xD;
&#xD;
          -  Autoimmune diseases or those who receiving immune suppressive treatment&#xD;
&#xD;
          -  Symptomatic neuropathy &gt; CTCAE grade 1&#xD;
&#xD;
          -  Those who consented other clinical trials within 3 months&#xD;
&#xD;
          -  Other significant medical conditions contraindicated to clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young-Chul Kim, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun</city>
        <state>Jeonnam</state>
        <zip>519-763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Medical Center</name>
      <address>
        <city>Daegu</city>
        <state>Kyungpook</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Pusan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kosin University Gospel Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea university Guro hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Kreuter M, Vansteenkiste J, Fischer JR, Eberhardt W, Zabeck H, Kollmeier J, Serke M, Frickhofen N, Reck M, Engel-Riedel W, Neumann S, Thomeer M, Schumann C, De Leyn P, Graeter T, Stamatis G, Zuna I, Griesinger F, Thomas M; TREAT investigators. Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. Ann Oncol. 2013 Apr;24(4):986-92. doi: 10.1093/annonc/mds578. Epub 2012 Nov 15.</citation>
    <PMID>23161898</PMID>
  </results_reference>
  <results_reference>
    <citation>Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, GonzÃ¡les-Larriba JL, Grodzki T, Pereira JR, Le Groumellec A, Lorusso V, Clary C, Torres AJ, Dahabreh J, Souquet PJ, Astudillo J, Fournel P, Artal-Cortes A, Jassem J, Koubkova L, His P, Riggi M, Hurteloup P. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006 Sep;7(9):719-27. Erratum in: Lancet Oncol. 2006 Oct;7(10):797.</citation>
    <PMID>16945766</PMID>
  </results_reference>
  <results_reference>
    <citation>Olaussen KA, Dunant A, Fouret P, Brambilla E, AndrÃ© F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC; IALT Bio Investigators. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006 Sep 7;355(10):983-91.</citation>
    <PMID>16957145</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 13, 2015</study_first_submitted>
  <study_first_submitted_qc>July 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2015</study_first_posted>
  <last_update_submitted>August 1, 2021</last_update_submitted>
  <last_update_submitted_qc>August 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chonnam National University Hospital</investigator_affiliation>
    <investigator_full_name>Young-Chul Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>adenocarcinoma</keyword>
  <keyword>lung</keyword>
  <keyword>adjuvant chemotherapy</keyword>
  <keyword>pemetrexed</keyword>
  <keyword>cisplatin</keyword>
  <keyword>surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

